Silo Pharma, Inc.

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on developing novel therapeutics and drug delivery systems to address underserved central nervous system (CNS) conditions. The company's mission centers on tackling stress-induced psychiatric disorders, chronic pain, and neurological diseases. Headquartered in Sarasota, Florida, Silo Pharma aims to bring innovative solutions to patients with limited treatment options.

The company's pipeline includes several key programs. SPC-15 is an intranasal formulation under development for Post-Traumatic Stress Disorder (PTSD) and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant being developed for fibromyalgia and chronic pain relief. Additionally, Silo Pharma has preclinical assets, including SPC-14 for Alzheimer's disease and SPU-16 for multiple sclerosis. The company's research and development efforts encompass both conventional drugs and psychedelic formulations, often in collaboration with leading academic institutions.

Recent notable developments for Silo Pharma include its strategic expansion into the AI agent market with the acquisition of the Qwikagents platform in April 2026. The company has also seen advancements in its PTSD program, SPC-15, following a U.S. executive order aimed at accelerating psychedelic research and securing a European patent for a novel PTSD prevention therapy in April 2026. Led by Founder and CEO Eric Weisblum, Silo Pharma is positioned as a company leveraging collaborations with institutions like Columbia University and the University of Maryland, Baltimore, to advance its therapeutic candidates and pursue a streamlined regulatory pathway for faster drug approval.